{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:06:46Z","timestamp":1793318806458,"version":"4.5.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"crossref","award":["No. 2020-2819"],"award-info":[{"award-number":["No. 2020-2819"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"crossref","award":["No. 2020-2819"],"award-info":[{"award-number":["No. 2020-2819"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"crossref","award":["No. BT\/RLF\/Re-entry\/58\/2017"],"award-info":[{"award-number":["No. BT\/RLF\/Re-entry\/58\/2017"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"crossref","award":["No. BT\/RLF\/Re-entry\/58\/2017"],"award-info":[{"award-number":["No. BT\/RLF\/Re-entry\/58\/2017"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-023-01014-3","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T12:04:26Z","timestamp":1676289866000},"page":"1901-1916","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Therapeutic options in hepatocellular carcinoma: a comprehensive review"],"prefix":"10.1007","volume":"23","author":[{"given":"Diwakar","family":"Suresh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshatha N.","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akila","family":"Prashant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuzhuvelil B.","family":"Harikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya P.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"1014_CR1","unstructured":"World Health Organization International Agency for Research on Cancer (IACR). GLOBOCAN 2020: estimated cancer incidence, mortality, and prevalence worldwide in 2020. Available at http:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/11-Liver-fact-sheet.pdf."},{"key":"1014_CR2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723\u201350.","journal-title":"Hepatology"},{"key":"1014_CR3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s15010-019-01345-y","volume":"48","author":"E Sagnelli","year":"2020","unstructured":"Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48:7\u201317.","journal-title":"Infection"},{"key":"1014_CR4","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","volume":"3","author":"Global Burden of Disease Liver Cancer Collaboration","year":"2017","unstructured":"Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3:1683\u201391.","journal-title":"JAMA Oncol"},{"key":"1014_CR5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1186\/s12885-021-08426-y","volume":"21","author":"OB Dakurah","year":"2021","unstructured":"Dakurah OB, Tamandjou CRT, Zunza M, Preiser W, Maponga TG. Viral hepatitis associated hepatocellular carcinoma on the African continent, the past, present, and future: a systematic review. BMC Cancer. 2021;21:715.","journal-title":"BMC Cancer"},{"key":"1014_CR6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3350\/cmh.2015.21.2.105","volume":"21","author":"N Goossens","year":"2015","unstructured":"Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol. 2015;21:105\u201314.","journal-title":"Clin Mol Hepatol"},{"key":"1014_CR7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2147\/JHC.S344559","volume":"9","author":"MI Ahmad","year":"2022","unstructured":"Ahmad MI, Khan MU, Kodali S, Shetty A, Bell SM, Victor D. Hepatocellular carcinoma due to nonalcoholic fatty liver disease: current concepts and future challenges. J Hepatocell Carcinoma. 2022;9:477\u201396.","journal-title":"J Hepatocell Carcinoma"},{"key":"1014_CR8","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S2468-1253(22)00050-4","volume":"7","author":"CJ Alberts","year":"2022","unstructured":"Alberts CJ, Clifford GM, Georges D, et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol Hepatol. 2022;7:724\u201335.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1014_CR9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/carcin\/17.5.1007","volume":"17","author":"Y Soini","year":"1996","unstructured":"Soini Y, Chia SC, Bennett WP, et al. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis. 1996;17:1007\u201312.","journal-title":"Carcinogenesis"},{"key":"1014_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/jcar.JCar_9_16","volume":"16","author":"YA Ghouri","year":"2017","unstructured":"Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1.","journal-title":"J Carcinog"},{"key":"1014_CR11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jceh.2019.01.004","volume":"9","author":"A Jindal","year":"2019","unstructured":"Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: etiology and current and future drugs. J Clin Exp Hepatol. 2019;9:221\u201332.","journal-title":"J Clin Exp Hepatol"},{"key":"1014_CR12","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.3748\/wjg.v20.i15.4115","volume":"20","author":"A Raza","year":"2014","unstructured":"Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol. 2014;20:4115\u201322.","journal-title":"World J Gastroenterol"},{"key":"1014_CR13","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4254\/wjh.v7.i3.406","volume":"7","author":"A Kinoshita","year":"2015","unstructured":"Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: current status and future perspectives. World J Hepatol. 2015;7:406\u201324.","journal-title":"World J Hepatol"},{"key":"1014_CR14","doi-asserted-by":"crossref","first-page":"601710","DOI":"10.3389\/fonc.2020.601710","volume":"10","author":"D Suresh","year":"2020","unstructured":"Suresh D, Srinivas AN, Kumar DP. Etiology of hepatocellular carcinoma: special focus on fatty liver disease. Front Oncol. 2020;10:601710.","journal-title":"Front Oncol"},{"key":"1014_CR15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000501749","volume":"35","author":"H Wege","year":"2019","unstructured":"Wege H, Li J, Ittrich H. Treatment lines in hepatocellular carcinoma. Visc Med. 2019;35:266\u201372.","journal-title":"Visc Med"},{"key":"1014_CR16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.21037\/hbsn-2021-7","volume":"10","author":"T Zhang","year":"2021","unstructured":"Zhang T, Merle P, Wang H, Zhao H, Kudo M. Combination therapy for advanced hepatocellular carcinoma: Do we see the light at the end of the tunnel? Hepatobiliary Surg Nutr. 2021;10:180\u201392.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"1014_CR17","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s11605-018-3690-4","volume":"22","author":"F Krenzien","year":"2018","unstructured":"Krenzien F, Schmelzle M, Struecker B, et al. Liver transplantation and liver resection for cirrhotic patients with hepatocellular carcinoma: comparison of long-term survivals. J Gastrointest Surg. 2018;22:840\u20138.","journal-title":"J Gastrointest Surg"},{"key":"1014_CR18","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.3748\/wjg.14.3452","volume":"14","author":"SG Delis","year":"2008","unstructured":"Delis SG, Dervenis C. Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease. World J Gastroenterol. 2008;14:3452\u201360.","journal-title":"World J Gastroenterol"},{"key":"1014_CR19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.hepres.2003.08.002","volume":"28","author":"I Ikai","year":"2004","unstructured":"Ikai I, Itai Y, Okita K, et al. Report of the 15th follow-up survey of primary liver cancer. Hepatol Res. 2004;28:21\u20139.","journal-title":"Hepatol Res"},{"key":"1014_CR20","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1002\/cncr.30237","volume":"122","author":"SP Choo","year":"2016","unstructured":"Choo SP, Tan WL, Goh BK, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430\u201346.","journal-title":"Cancer"},{"key":"1014_CR21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2147\/JHC.S370212","volume":"9","author":"IJY Wee","year":"2022","unstructured":"Wee IJY, Moe FNN, Sultana R, et al. Extending surgical resection for hepatocellular carcinoma beyond Barcelona clinic for liver cancer (BCLC) Stage A: A novel application of the modified BCLC staging system. J Hepatocell Carcinoma. 2022;9:839\u201351.","journal-title":"J Hepatocell Carcinoma"},{"key":"1014_CR22","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.gastro.2009.06.003","volume":"137","author":"S Roayaie","year":"2009","unstructured":"Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137:850\u20135.","journal-title":"Gastroenterology"},{"key":"1014_CR23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.14218\/JCTH.2019.00050","volume":"8","author":"VA Lingiah","year":"2020","unstructured":"Lingiah VA, Niazi M, Olivo R, Paterno F, Guarrera JV, Pyrsopoulos NT. Liver transplantation beyond Milan criteria. J Clin Transl Hepatol. 2020;8:69\u201375.","journal-title":"J Clin Transl Hepatol"},{"key":"1014_CR24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzaferro","year":"1996","unstructured":"Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693\u20139.","journal-title":"N Engl J Med"},{"issue":"31","key":"1014_CR25","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/tri.13358","volume":"2018","author":"R Adam","year":"2018","unstructured":"Adam R, Karam V, Cailliez V, et al. Annual Report of the European Liver Transplant Registry (ELTR)\u201350-year evolution of liver transplantation. Transpl Int. 2018;2018(31):1293\u2013317.","journal-title":"Transpl Int"},{"key":"1014_CR26","unstructured":"Organ Procurement and Transplantation Network. Liver transplantation. Available at: https:\/\/optn.transplant.hrsa.gov"},{"key":"1014_CR27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4254\/wjh.v8.i3.191","volume":"8","author":"MJ Ryan","year":"2016","unstructured":"Ryan MJ, Willatt J, Majdalany BS, Kielar AZ, Chong S, Ruma JA, Pandya A. Ablation techniques for primary and metastatic liver tumors. World J Hepatol. 2016;8:191\u20139.","journal-title":"World J Hepatol"},{"key":"1014_CR28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jceh.2014.03.046","volume":"4","author":"RB Thandassery","year":"2014","unstructured":"Thandassery RB, Goenka U, Goenka MK. Role of local ablative therapy for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:104\u201311.","journal-title":"J Clin Exp Hepatol"},{"key":"1014_CR29","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/gut.2004.045203","volume":"54","author":"SM Lin","year":"2005","unstructured":"Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54:1151\u20136.","journal-title":"Gut"},{"key":"1014_CR30","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/hpb.12446","volume":"17","author":"JT Miura","year":"2015","unstructured":"Miura JT, Johnston FM, Tsai S, et al. Surgical resection versus ablation for hepatocellular carcinoma\u2264 3 cm: a population-based analysis. HPB (Oxford). 2015;17:896\u2013901.","journal-title":"HPB (Oxford)"},{"key":"1014_CR31","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11605-007-0392-8","volume":"12","author":"A Guglielmi","year":"2008","unstructured":"Guglielmi A, Ruzzenente A, Valdegamberi A, et al. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J Gastrointest Surg. 2008;12:192\u20138.","journal-title":"J Gastrointest Surg"},{"key":"1014_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.crad.2012.06.112","volume":"68","author":"J Kritzinger","year":"2013","unstructured":"Kritzinger J, Klass D, Ho S, et al. Hepatic embolotherapy in interventional oncology: technology, techniques, and applications. Clin Radiol. 2013;68:1\u201315.","journal-title":"Clin Radiol"},{"key":"1014_CR33","unstructured":"American Cancer Society. Available at: https:\/\/www.cancer.org\/cancer\/liver-cancer\/treating\/embolization-therapy.html"},{"key":"1014_CR34","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3390\/cancers12040791","volume":"12","author":"SA Kishore","year":"2020","unstructured":"Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic strategies for hepatocellular carcinoma: 2020 update. Cancers. 2020;12:791.","journal-title":"Cancers"},{"key":"1014_CR35","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2217\/hep.15.32","volume":"2","author":"F Chegai","year":"2015","unstructured":"Chegai F, Orlacchio A, Merolla S, Monti S, Mannelli L. Intermediate hepatocellular carcinoma: the role of transarterial therapy. Hepat Oncol. 2015;2:399\u2013408.","journal-title":"Hepat Oncol"},{"key":"1014_CR36","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1148\/radiology.148.2.6306721","volume":"148","author":"R Yamada","year":"1983","unstructured":"Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983;148:397\u2013401.","journal-title":"Radiology"},{"key":"1014_CR37","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.jvir.2007.08.027","volume":"18","author":"DB Brown","year":"2007","unstructured":"Brown DB, Gould JE, Gervais DA, et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2007;18:1469\u201378.","journal-title":"J Vasc Interv Radiol"},{"key":"1014_CR38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40644-017-0108-6","volume":"17","author":"JH Luz","year":"2017","unstructured":"Luz JH, Luz PM, Martin HS, et al. DEB TACE for intermediate and advanced HCC\u2013initial experience in a Brazilian cancer center. Cancer Imaging. 2017;17:5.","journal-title":"Cancer Imaging"},{"key":"1014_CR39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00270-006-0062-3","volume":"30","author":"L Marelli","year":"2007","unstructured":"Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radio. 2007;30:6\u201325.","journal-title":"Cardiovasc Intervent Radio"},{"key":"1014_CR40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","volume":"33","author":"J Lammer","year":"2010","unstructured":"Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41\u201352.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1014_CR41","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Monta\u00f1a X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. The Lancet. 2002;359:1734\u20139.","journal-title":"The Lancet"},{"key":"1014_CR42","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164\u201371.","journal-title":"Hepatology"},{"key":"1014_CR43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrclinonc.2012.203","volume":"10","author":"J Thariat","year":"2013","unstructured":"Thariat J, Hannoun-Levi JM, Myint AS, Vuong T, G\u00e9rard JP. Past, present, and future of radiotherapy for the benefit of patients. Nat Rev Clin Oncol. 2013;10:52.","journal-title":"Nat Rev Clin Oncol"},{"key":"1014_CR44","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.2147\/CMAR.S175703","volume":"10","author":"CH Rim","year":"2018","unstructured":"Rim CH, Kim CY, Yang DS, Yoon WS. The role of external beam radiotherapy for hepatocellular carcinoma patients with lymph node metastasis: a meta-analysis of observational studies. Cancer Manag Res. 2018;10:3305\u201315.","journal-title":"Cancer Manag Res"},{"key":"1014_CR45","first-page":"91","volume":"76","author":"S Hayashi","year":"2014","unstructured":"Hayashi S, Tanaka H, Hoshi H. External beam radiotherapy for painful bone metastases from hepatocellular carcinoma: multiple fractions compared with an 8-Gy single fraction. Nagoya J Med Sci. 2014;76:91\u20139.","journal-title":"Nagoya J Med Sci"},{"key":"1014_CR46","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1111\/j.1572-0241.1998.00614.x","volume":"93","author":"T Kaizu","year":"1998","unstructured":"Kaizu T, Karasawa K, Tanaka Y, Matuda T, Kurosaki H, Tanaka S, Kumazaki T. Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients. Am J Gastroenterol. 1998;93:2167\u201371.","journal-title":"Am J Gastroenterol"},{"key":"1014_CR47","doi-asserted-by":"crossref","first-page":"e3789","DOI":"10.1097\/MD.0000000000003789","volume":"95","author":"T Zhang","year":"2016","unstructured":"Zhang T, Zhao YT, Wang Z, et al. Efficacy and safety of intensity-modulated radiotherapy following transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Medicine (Baltimore). 2016;95:e3789.","journal-title":"Medicine (Baltimore)"},{"key":"1014_CR48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/1748-717X-8-250","volume":"8","author":"WI Jang","year":"2013","unstructured":"Jang WI, Kim MS, Bae SH, et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol. 2013;8:250.","journal-title":"Radiat Oncol"},{"key":"1014_CR49","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5009\/gnl.2013.7.3.343","volume":"7","author":"M Kong","year":"2013","unstructured":"Kong M, Hong SE, Choi WS, Choi J, Kim Y. Treatment outcomes of helical intensity-modulated radiotherapy for unresectable hepatocellular carcinoma. Gut Liver. 2013;7:343\u201351.","journal-title":"Gut Liver"},{"key":"1014_CR50","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijrobp.2017.09.001","volume":"100","author":"E Sapir","year":"2018","unstructured":"Sapir E, Tao Y, Schipper MJ, et al. Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2018;100:122\u201330.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1014_CR51","unstructured":"National Cancer Institute. Chemotherapy to treat cancer. Available at: https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/chemotherapy"},{"key":"1014_CR52","first-page":"246","volume":"8","author":"S Shaaban","year":"2014","unstructured":"Shaaban S, Negm A, Ibrahim EE, Elrazak AA. Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action. Oncol Rev. 2014;8:246.","journal-title":"Oncol Rev"},{"key":"1014_CR53","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00280-004-0837-7","volume":"54","author":"J Lee","year":"2004","unstructured":"Lee J, Park JO, Kim WS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol. 2004;54:385\u201390.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1014_CR54","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdf303","volume":"13","author":"TS Yang","year":"2002","unstructured":"Yang TS, Wang CH, Hsieh RK, Chen JS, Fung MC. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial. Ann Oncol. 2002;13:1771\u20138.","journal-title":"Ann Oncol"},{"key":"1014_CR55","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s002800050982","volume":"44","author":"TS Mok","year":"1999","unstructured":"Mok TS, Leung TW, Lee SD, et al. A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 1999;44:307\u201311.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1014_CR56","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-003-1303-8","volume":"39","author":"TS Yang","year":"2004","unstructured":"Yang TS, Chang HK, Chen JS, Lin YC, Liau CT, Chang WC. Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. J Gastroenterol. 2004;39:362\u20139.","journal-title":"J Gastroenterol"},{"key":"1014_CR57","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jhep.2011.07.031","volume":"56","author":"T Asghar","year":"2012","unstructured":"Asghar T, Meyer T. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol. 2012;56:686\u201395.","journal-title":"J Hepatol"},{"key":"1014_CR58","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3350\/cmh.2014.20.3.317","volume":"20","author":"A Sharma","year":"2014","unstructured":"Sharma A, Houshyar R, Bhosale P, Choi JI, Gulati R, Lall C. Chemotherapy induced liver abnormalities: an imaging perspective. Clin Mol Hepatol. 2014;20:317\u201326.","journal-title":"Clin Mol Hepatol"},{"key":"1014_CR59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.bjc.6604784","volume":"100","author":"TF Greten","year":"2009","unstructured":"Greten TF, Korangy F, Manns MP, Malek NP. Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer. 2009;100:19\u201323.","journal-title":"Br J Cancer"},{"key":"1014_CR60","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/hepr.12459","volume":"45","author":"M Chuma","year":"2015","unstructured":"Chuma M, Terashita K, Sakamoto N. New molecularly targeted therapies against advanced hepatocellular carcinoma: from molecular pathogenesis to clinical trials and future directions. Hepat Res. 2015;45:E1-1.","journal-title":"Hepat Res"},{"key":"1014_CR61","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000342405","volume":"1","author":"A Moeini","year":"2012","unstructured":"Moeini A, Cornell\u00e0 H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver cancer. 2012;1:83\u201393.","journal-title":"Liver cancer"},{"key":"1014_CR62","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1038\/onc.2010.236","volume":"29","author":"S Whittaker","year":"2010","unstructured":"Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010;29:4989\u20135005.","journal-title":"Oncogene"},{"key":"1014_CR63","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","volume":"11","author":"DB Fogel","year":"2018","unstructured":"Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11:156\u201364.","journal-title":"Contemp Clin Trials Commun"},{"key":"1014_CR64","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"1014_CR65","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jhep.2011.12.009","volume":"56","author":"JL Raoul","year":"2012","unstructured":"Raoul JL, Bruix J, Greten TF, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol. 2012;56:1080\u20138.","journal-title":"J Hepatol"},{"key":"1014_CR66","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","volume":"65","author":"JA Marrero","year":"2016","unstructured":"Marrero JA, Kudo M, Venook AP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. J Hepatol. 2016;65:1140\u20137.","journal-title":"J Hepatol"},{"key":"1014_CR67","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al. RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56\u201366.","journal-title":"Lancet"},{"key":"1014_CR68","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JCO.2018.36.4_suppl.207","volume":"36","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial. J Clin Oncol. 2018;36:207.","journal-title":"J Clin Oncol"},{"key":"1014_CR69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000487148","volume":"7","author":"M Kudo","year":"2018","unstructured":"Kudo M. Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma. Liver Cancer. 2018;7:1\u20139.","journal-title":"Liver Cancer"},{"key":"1014_CR70","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1200\/JCO.2020.38.15_suppl.4506","volume":"38","author":"F Bi","year":"2020","unstructured":"Bi F, Qin S, Gu S, et al. Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: an open-label, randomized, multicenter phase II\/III trial. J Clin Oncol. 2020;38:4506\u2013606.","journal-title":"J Clin Oncol"},{"key":"1014_CR71","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.ejca.2013.05.028","volume":"49","author":"J Bruix","year":"2013","unstructured":"Bruix J, Tak WY, Gasbarrini A, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer. 2013;49:3412\u20139.","journal-title":"Eur J Cancer"},{"key":"1014_CR72","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1021\/jm7013309","volume":"51","author":"ZW Cai","year":"2008","unstructured":"Cai ZW, Zhang Y, Borzilleri RM, et al. Discovery of brivanib alaninate, a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem. 2008;51:1976\u201380.","journal-title":"J Med Chem"},{"key":"1014_CR73","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54\u201363.","journal-title":"N Engl J Med"},{"key":"1014_CR74","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2217\/fon-2020-0726","volume":"17","author":"V Merz","year":"2021","unstructured":"Merz V, Zecchetto C, Melisi D. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma. Future Oncol. 2021;17:389\u2013402.","journal-title":"Future Oncol"},{"key":"1014_CR75","doi-asserted-by":"crossref","first-page":"105596","DOI":"10.18632\/oncotarget.22337","volume":"8","author":"Y Kong","year":"2017","unstructured":"Kong Y, Sun L, Hou Z, et al. Apatinib is effective for treatment of advanced hepatocellular carcinoma. Oncotarget. 2017;8:105596\u2013605.","journal-title":"Oncotarget"},{"key":"1014_CR76","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncol. 2019;20:282\u201396.","journal-title":"The Lancet Oncol"},{"key":"1014_CR77","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","volume":"26","author":"AB Siegel","year":"2008","unstructured":"Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26:2992.","journal-title":"J Clin Oncol"},{"key":"1014_CR78","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.3390\/cancers12102859","volume":"12","author":"C Kole","year":"2020","unstructured":"Kole C, Charalampakis N, Tsakatikas S, et al. Immunotherapy for hepatocellular carcinoma: a 2021 update. Cancers. 2020;12:2859.","journal-title":"Cancers"},{"key":"1014_CR79","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/vaccines8040616","volume":"8","author":"MA Aziz","year":"2020","unstructured":"Aziz MA, Facciorusso A, Nayfeh T, et al. Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Vaccines. 2020;8:616.","journal-title":"Vaccines"},{"key":"1014_CR80","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. The Lancet. 2017;389:2492\u2013502.","journal-title":"The Lancet"},{"key":"1014_CR81","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. The Lancet Oncol. 2018;19:940\u201352.","journal-title":"The Lancet Oncol"},{"key":"1014_CR82","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. The Lancet Oncol. 2020;21:571\u201380.","journal-title":"The Lancet Oncol"},{"key":"1014_CR83","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","volume":"21","author":"MS Lee","year":"2020","unstructured":"Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. The Lancet Oncol. 2020;21:808\u201320.","journal-title":"The Lancet Oncol"},{"key":"1014_CR84","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6:e204564.","journal-title":"JAMA Oncol"},{"key":"1014_CR85","first-page":"428","volume":"7","author":"M Berretta","year":"2016","unstructured":"Berretta M, Rinaldi L, Di Benedetto F, et al. Angiogenesis inhibitors for the treatment of hepatocellular carcinoma. Front Pharmacol. 2016;7:428.","journal-title":"Front Pharmacol"},{"key":"1014_CR86","first-page":"1254","volume":"9","author":"CC Jia","year":"2019","unstructured":"Jia CC, Chen YH, Cai XR, et al. Efficacy of cytokine-induced killer cell-based immunotherapy for hepatocellular carcinoma. Am J Cancer Res. 2019;9:1254\u201365.","journal-title":"Am J Cancer Res"},{"key":"1014_CR87","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1158\/2326-6066.CIR-18-0757","volume":"7","author":"H Sun","year":"2019","unstructured":"Sun H, Liu L, Huang Q, et al. Accumulation of tumor-infiltrating CD49a+ NK cells correlates with poor prognosis for human hepatocellular carcinoma. Cancer Immunol Res. 2019;7:1535\u201346.","journal-title":"Cancer Immunol Res"},{"key":"1014_CR88","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","volume":"26","author":"D Shi","year":"2020","unstructured":"Shi D, Shi Y, Kaseb AO, et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials. Clin Cancer Res. 2020;26:3979\u201389.","journal-title":"Clin Cancer Res"},{"key":"1014_CR89","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0140-6736(00)02654-4","volume":"356","author":"T Takayama","year":"2000","unstructured":"Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. The Lancet. 2000;356:802\u20137.","journal-title":"The Lancet"},{"key":"1014_CR90","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","volume":"180","author":"S Wilkie","year":"2008","unstructured":"Wilkie S, Picco G, Foster J, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol. 2008;180:4901\u20139.","journal-title":"J Immunol"},{"key":"1014_CR91","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/cancers13020271","volume":"13","author":"P Rochigneux","year":"2021","unstructured":"Rochigneux P, Chanez B, De Rauglaudre B, Mitry E, Chabannon C, Gilabert M. Adoptive cell therapy in hepatocellular carcinoma: biological rationale and first results in early phase clinical trials. Cancers. 2021;13:271.","journal-title":"Cancers"},{"key":"1014_CR92","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.3748\/wjg.v25.i24.2977","volume":"25","author":"MP Johnston","year":"2019","unstructured":"Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: Current and future. World J Gastroenterol. 2019;25:2977\u201389.","journal-title":"World J Gastroenterol"},{"key":"1014_CR93","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1189\/jlb.0506297","volume":"80","author":"A Budhu","year":"2006","unstructured":"Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol. 2006;80:1197\u2013213.","journal-title":"J Leukoc Biol"},{"key":"1014_CR94","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/bjc.2013.781","volume":"110","author":"ZY Chen","year":"2014","unstructured":"Chen ZY, Wei W, Guo ZX, et al. Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. Br J Cancer. 2014;110:733\u201340.","journal-title":"Br J Cancer"},{"key":"1014_CR95","first-page":"4531","volume":"33","author":"B Tomov","year":"2013","unstructured":"Tomov B, Popov D, Tomova R, Vladov N, Den Otter W, Krastev Z. Therapeutic response of untreatable hepatocellular carcinoma after application of the immune modulators IL-2. BCG Melatonin Anticancer Res. 2013;33:4531\u20135.","journal-title":"BCG Melatonin Anticancer Res"},{"key":"1014_CR96","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3390\/cancers11121865","volume":"11","author":"K Kamimura","year":"2019","unstructured":"Kamimura K, Yokoo T, Abe H, Terai S. Gene therapy for liver cancers: current status from basic to clinics. Cancers. 2019;11:1865.","journal-title":"Cancers"},{"key":"1014_CR97","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3390\/cancers11091265","volume":"11","author":"SC Reghupaty","year":"2019","unstructured":"Reghupaty SC, Sarkar D. Current status of gene therapy in hepatocellular carcinoma. Cancers. 2019;11:1265.","journal-title":"Cancers"},{"key":"1014_CR98","first-page":"8619096","volume":"26","author":"Z Xu","year":"2019","unstructured":"Xu Z, Xie H, Zhou L, Chen X, Zheng S. The combination strategy of transarterial chemoembolization and radiofrequency ablation or microwave ablation against hepatocellular carcinoma. Anal Cell Pathol. 2019;26:8619096.","journal-title":"Anal Cell Pathol"},{"key":"1014_CR99","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3348\/kjr.2016.17.1.93","volume":"17","author":"X Wang","year":"2016","unstructured":"Wang X, Hu Y, Ren M, Lu X, Lu G, He S. Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: a time-to-event meta-analysis. Korean J Radiol. 2016;17:93.","journal-title":"Korean J Radiol"},{"key":"1014_CR100","first-page":"471","volume":"26","author":"HC Liu","year":"2014","unstructured":"Liu HC, Shan EB, Zhou L, et al. Combination of percutaneous radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: observation of clinical effects. Chin J Cancer Res. 2014;26:471.","journal-title":"Chin J Cancer Res"},{"key":"1014_CR101","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1148\/radiol.2018172028","volume":"288","author":"K Zhu","year":"2018","unstructured":"Zhu K, Huang J, Lai L, et al. Medium or large hepatocellular carcinoma: sorafenib combined with transarterial chemoembolization and radiofrequency ablation. Radiology. 2018;288:300\u20137.","journal-title":"Radiology"},{"key":"1014_CR102","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","volume":"66","author":"AG Duffy","year":"2017","unstructured":"Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66:545\u201351.","journal-title":"J Hepatol"},{"key":"1014_CR103","first-page":"2577","volume":"11","author":"YH Lee","year":"2020","unstructured":"Lee YH, Tai D, Yip C, Choo SP, Chew V. Combinational immunotherapy for hepatocellular carcinoma: radiotherapy, immune checkpoint blockade and beyond. Front Immunol. 2020;11:2577.","journal-title":"Front Immunol"},{"key":"1014_CR104","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.3748\/wjg.v21.i21.6518","volume":"21","author":"R Sacco","year":"2015","unstructured":"Sacco R, Mismas V, Marceglia S, et al. Transarterial radioembolization for hepatocellular carcinoma: an update and perspectives. World J Gastroenterol. 2015;21:6518.","journal-title":"World J Gastroenterol"},{"key":"1014_CR105","first-page":"2961","volume":"35","author":"S Hinz","year":"2015","unstructured":"Hinz S, Tepel J, Roeder C, Kalthoff H, Becker T. Profile of serum factors and disseminated tumor cells before and after radiofrequency ablation compared to resection of colorectal liver metastases-a pilot study. Anticancer Res. 2015;35:2961\u20137.","journal-title":"Anticancer Res"},{"key":"1014_CR106","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1148\/radiol.2019182326","volume":"292","author":"JP Erinjeri","year":"2019","unstructured":"Erinjeri JP, Fine GC, Adema GJ, et al. Immunotherapy and the interventional oncologist: challenges and opportunities\u2014a society of interventional oncology white paper. Radiology. 2019;292:25\u201334.","journal-title":"Radiology"},{"key":"1014_CR107","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jvir.2019.05.023","volume":"31","author":"C Zhan","year":"2020","unstructured":"Zhan C, Ruohoniemi D, Shanbhogue KP, et al. Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma. J Vasc Interv Radiol. 2020;31:25\u201334.","journal-title":"J Vasc Interv Radiol"},{"key":"1014_CR108","doi-asserted-by":"crossref","first-page":"930868","DOI":"10.3389\/fonc.2022.930868","volume":"12","author":"W Li","year":"2022","unstructured":"Li W, Pei Y, Wang Z, Liu J. Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:930868.","journal-title":"Front Oncol"},{"key":"1014_CR109","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3390\/cancers11070985","volume":"11","author":"VC Kok","year":"2019","unstructured":"Kok VC, Chen YC, Chen YY, et al. Sorafenib with transarterial chemoembolization achieves improved survival vs. sorafenib alone in advanced hepatocellular carcinoma: a nationwide population-based cohort study. Cancers. 2019;11:985.","journal-title":"Cancers"},{"key":"1014_CR110","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jhep.2012.01.006","volume":"56","author":"JW Park","year":"2012","unstructured":"Park JW, Koh YH, Kim HB, et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol. 2012;56:1336\u201342.","journal-title":"J Hepatol"},{"key":"1014_CR111","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00280-014-2568-8","volume":"74","author":"AK Erhardt","year":"2014","unstructured":"Erhardt AK, Kolligs FT, Dollinger MM, et al. TACE plus sorafenib for the treatment of hepatocellular carcinoma: final results of the multicenter, phase II SOCRATES trial. Cancer Chemother Pharmacol. 2014;74:947\u201354.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1014_CR112","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.radonc.2017.11.027","volume":"129","author":"HJ Kim","year":"2018","unstructured":"Kim HJ, Park S, Kim KJ, Seong J. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. Radiother Oncol. 2018;129:130\u20135.","journal-title":"Radiother Oncol"},{"key":"1014_CR113","doi-asserted-by":"crossref","first-page":"e92572","DOI":"10.1371\/journal.pone.0092572","volume":"9","author":"Y Yoshimoto","year":"2014","unstructured":"Yoshimoto Y, Suzuki Y, Mimura K, et al. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS ONE. 2014;9:e92572.","journal-title":"PLoS ONE"},{"key":"1014_CR114","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fonc.2019.01157","volume":"9","author":"CL Chiang","year":"2019","unstructured":"Chiang CL, Chan AC, Chiu KW, Kong FM. Combined stereotactic body radiotherapy and checkpoint inhibition in unresectable hepatocellular carcinoma: a potential synergistic treatment strategy. Front Oncol. 2019;9:1157.","journal-title":"Front Oncol"},{"key":"1014_CR115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jimed.2019.09.006","volume":"2","author":"S Kang","year":"2019","unstructured":"Kang S, Bai X, Chen S, Song Y, Liu L. The potential combinational immunotherapies for treatment of hepatocellular carcinoma. J Intervent Med. 2019;2:47\u201351.","journal-title":"J Intervent Med"},{"key":"1014_CR116","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1016\/j.annonc.2020.04.429","volume":"31","author":"B Sangro","year":"2020","unstructured":"Sangro B, Kudo M, Qin S, et al. A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma (HCC). EMERALD-1. Ann Oncol. 2020;31:S202\u20133.","journal-title":"Ann Oncol"},{"key":"1014_CR117","doi-asserted-by":"crossref","first-page":"TPS4144","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS4144","volume":"36","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Chan SL, Furuse J, et al. A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. J Clin Oncol. 2018;36:TPS4144.","journal-title":"J Clin Oncol"},{"key":"1014_CR118","doi-asserted-by":"crossref","first-page":"100562","DOI":"10.1016\/j.esmoop.2022.100562","volume":"7","author":"M Simonelli","year":"2022","unstructured":"Simonelli M, Garralda E, Eskens F, et al. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I\/II, open-label, multicenter study. ESMO Open. 2022;7:100562.","journal-title":"ESMO Open"},{"key":"1014_CR119","unstructured":"Ghassan KA, George L, Masatoshi K, et al (2022) Tremelimumab plus Durvalumab in Unresectable Hepatocellular carcinoma. NEJM Evid. EVIDoa2100070."},{"key":"1014_CR120","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jamaoncol.2019.2792","volume":"5","author":"GK Abou-Alfa","year":"2019","unstructured":"Abou-Alfa GK, Shi Q, Knox JJ, et al. Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: phase 3 CALGB 80802 randomized clinical trial. JAMA Oncol. 2019;5:1582\u20138.","journal-title":"JAMA Oncol"},{"key":"1014_CR121","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2010.1672","volume":"304","author":"GK Abou-Alfa","year":"2010","unstructured":"Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304:2154\u201360.","journal-title":"JAMA"},{"key":"1014_CR122","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.2013.53.7746","volume":"33","author":"AX Zhu","year":"2014","unstructured":"Zhu AX, Rosmorduc O, Evans TR, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2014;33:559\u201366.","journal-title":"J Clin Oncol"},{"key":"1014_CR123","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2017;389:56\u201366.","journal-title":"The Lancet"},{"key":"1014_CR124","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s13046-019-1412-8","volume":"38","author":"Z Liu","year":"2019","unstructured":"Liu Z, Lin Y, Zhang J, et al. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J Exp Clinical Cancer Res. 2019;38:447.","journal-title":"J Exp Clinical Cancer Res"},{"key":"1014_CR125","doi-asserted-by":"crossref","first-page":"e001435","DOI":"10.1136\/jitc-2020-001435","volume":"8","author":"K Shigeta","year":"2020","unstructured":"Shigeta K, Matsui A, Kikuchi H, et al. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J Immunother Cancer. 2020;8:e001435.","journal-title":"J Immunother Cancer"},{"key":"1014_CR126","first-page":"894","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:894\u2013905.","journal-title":"N Engl J Med"},{"key":"1014_CR127","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38:2960\u201370.","journal-title":"J Clin Oncol"},{"key":"1014_CR128","unstructured":"Lisa Astor. FDD holds off on approval of Pembrolizumab\/ Lenvatinib for frontline unresectable HCC. Targeted Oncology. 2020. https:\/\/www.targetedonc.com\/view\/fda-denies-approval-of-pembrolizumab-lenvatinib-for-frontline-unresectable-hcc."}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01014-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01014-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01014-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T04:04:03Z","timestamp":1696133043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01014-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":128,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["1014"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01014-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"assertion":[{"value":"14 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}